Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
Background: The distribution of adverse events (AEs) triggered by immune checkpoint inhibitors (ICIs) across different cancer types has never been demonstrated. Methods: Randomised controlled trials exclusively assessing ICI monotherapy in cohorts of over 100 patients were considered. Our primary ou...
Saved in:
Main Authors: | Xuhui Tong, Rong Tang, Jin Xu, Wei Wang, Qiong Du, Si Shi, Xianjun Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Heliyon |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024176281 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01) -
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01) -
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
by: Douglas B Johnson, et al.
Published: (2024-07-01) -
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01) -
Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)